New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Learn More
Last Close
Oct 21  •  04:00PM ET
12.77
Dollar change
+0.63
Percentage change
5.19
%
Index- P/E- EPS (ttm)-76.67 Insider Own5.09% Shs Outstand1.88M Perf Week11.82%
Market Cap24.01M Forward P/E- EPS next Y-3.40 Insider Trans0.00% Shs Float1.79M Perf Month35.85%
Enterprise Value5.59M PEG- EPS next Q-3.28 Inst Own15.14% Short Float5.15% Perf Quarter53.86%
Income-26.31M P/S- EPS this Y81.59% Inst Trans15.31% Short Ratio1.07 Perf Half Y-76.13%
Sales0.00M P/B1.35 EPS next Y70.31% ROA-191.21% Short Interest0.09M Perf YTD-84.93%
Book/sh9.49 P/C1.34 EPS next 5Y70.73% ROE-339.54% 52W High190.50 -93.30% Perf Year-89.93%
Cash/sh9.51 P/FCF- EPS past 3/5Y37.91% 39.57% ROIC-147.15% 52W Low6.00 112.83% Perf 3Y-98.71%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility8.32% 7.29% Perf 5Y-98.48%
Dividend TTM- EV/Sales- EPS Y/Y TTM-75.54% Oper. Margin- ATR (14)0.87 Perf 10Y-
Dividend Ex-Date- Quick Ratio5.01 Sales Y/Y TTM- Profit Margin- RSI (14)63.69 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio5.01 EPS Q/Q57.49% SMA206.63% Beta1.20 Target Price95.00
Payout- Debt/Eq0.00 Sales Q/Q- SMA5034.00% Rel Volume6.00 Prev Close12.14
Employees17 LT Debt/Eq0.00 EarningsOct 15 BMO SMA200-56.67% Avg Volume85.85K Price12.77
IPOOct 28, 2010 Option/ShortNo / Yes EPS/Sales Surpr.0.00% - Trades Volume478,714 Change5.19%
Date Action Analyst Rating Change Price Target Change
Feb-14-22Initiated H.C. Wainwright Buy $25
Oct-21-25 07:50AM
07:30AM
Oct-20-25 07:30AM
Oct-13-25 07:30AM
Oct-03-25 07:30AM
12:00PM Loading…
Sep-12-25 12:00PM
Aug-26-25 07:30AM
Aug-25-25 07:30AM
Aug-21-25 12:00PM
Aug-13-25 07:30AM
Aug-05-25 08:17PM
Jul-31-25 07:30AM
Jul-30-25 07:30AM
Jul-29-25 07:30AM
Jul-25-25 07:30AM
04:05PM Loading…
Jul-16-25 04:05PM
Jul-15-25 03:40PM
03:30PM
03:05PM
07:30AM
Jul-11-25 07:30AM
Jul-10-25 07:30AM
Jul-09-25 07:30AM
Jul-08-25 07:30AM
Jul-02-25 07:30AM
Jun-24-25 07:30AM
Jun-04-25 07:30AM
Jun-02-25 07:30AM
May-27-25 07:30AM
May-23-25 07:30AM
07:30AM Loading…
May-20-25 07:30AM
May-01-25 11:04AM
Apr-30-25 07:30AM
Apr-28-25 04:05PM
07:30AM
Apr-24-25 08:00PM
07:30AM
Apr-23-25 07:30AM
Apr-22-25 07:30AM
Apr-16-25 07:30AM
Apr-10-25 08:00AM
Mar-26-25 08:00AM
Mar-20-25 08:00AM
Feb-05-25 06:15PM
04:05PM
Feb-03-25 07:59PM
04:45PM
07:30AM
Jan-27-25 06:42PM
Jan-03-25 05:05PM
05:05PM
Dec-17-24 04:05PM
04:05PM
Dec-13-24 04:05PM
07:50AM
Dec-11-24 11:54PM
04:05PM
07:50AM
Dec-02-24 10:18AM
07:50AM
Nov-26-24 07:50AM
Nov-25-24 07:50AM
Nov-21-24 07:50AM
Nov-08-24 07:50AM
Nov-04-24 07:50AM
Oct-22-24 07:50AM
Oct-15-24 07:50AM
Oct-02-24 04:05PM
Oct-01-24 02:05PM
07:50AM
Sep-18-24 07:50AM
Sep-12-24 04:05PM
Sep-11-24 12:09PM
07:50AM
Sep-10-24 07:50AM
Sep-09-24 07:50AM
Jul-18-24 07:56AM
Jun-14-24 09:52PM
Jun-03-24 08:00AM
May-30-24 08:00AM
May-28-24 08:00AM
07:27AM
May-24-24 08:00AM
May-21-24 07:39AM
May-17-24 04:33PM
May-15-24 08:00AM
Apr-24-24 08:00AM
Apr-10-24 08:00AM
Apr-09-24 08:00AM
Mar-19-24 06:52AM
Mar-07-24 08:00AM
Mar-06-24 08:00AM
Feb-27-24 08:00AM
Feb-07-24 08:00AM
Feb-06-24 08:30AM
Jan-30-24 10:48PM
Jan-04-24 08:45AM
Dec-28-23 08:55AM
Dec-20-23 08:40AM
Dec-06-23 09:31AM
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.